RecruitingPhase 2NCT07148414

A Study of SPY072 in Rheumatic Disease

Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease

Sponsor

Spyre Therapeutics, Inc.

Enrollment

285 participants

Start Date

Aug 21, 2025

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis Psoriatic Arthritis Rheumatic Diseases Axial Spondyloarthritis Rheumatic Joint Disease PsA (Psoriatic Arthritis)AxSpA Rheumatologic Disease

Summary

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called SPY072 in people with rheumatic diseases — specifically rheumatoid arthritis, axial spondyloarthritis (a type of inflammatory back pain), or systemic lupus erythematosus. These are all autoimmune conditions where the immune system attacks the body. **You may be eligible if...** - You have been diagnosed with rheumatoid arthritis, axial spondyloarthritis, or lupus (SLE) - Your disease is moderately to severely active despite previous treatment - For RA: you have 4 or more swollen and 4 or more tender joints, and have had an inadequate response to at least one DMARD (disease-modifying drug) - For axSpA: your disease is active with inadequate response to prior therapies **You may NOT be eligible if...** - You have tried more than 2 classes of biologic or targeted synthetic DMARDs - You have significant infections, organ damage, or other conditions that make the drug unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSPY002-072

Experimental

DRUGPlacebo

Matching Placebo

Locations(57)

Site 113

Avondale, Arizona, United States

Site 118

Tucson, Arizona, United States

Site 114

Chula Vista, California, United States

Site 111

Covina, California, United States

Site 108

Tujunga, California, United States

Site 112

Upland, California, United States

Site 107

Whittier, California, United States

Site 115

Aventura, Florida, United States

Site 109

Hialeah, Florida, United States

Site 106

Ormond Beach, Florida, United States

Site 110

Tampa, Florida, United States

Site 116

Willowbrook, Illinois, United States

Site 119

Rockville, Maryland, United States

Site 104

Duncansville, Pennsylvania, United States

Site 105

Corpus Christi, Texas, United States

Site 120

Irving, Texas, United States

Site 103

Tomball, Texas, United States

Site 102

Tomball, Texas, United States

Site 503

Lovech, Lovech, Bulgaria

Site 502

Pleven, Pleven, Bulgaria

Site 506

Plovdiv, Plovdiv, Bulgaria

Site 505

Plovdiv, Plovdiv, Bulgaria

Site 504

Varna, Varna, Bulgaria

Site 706

Hlučín, Hlučín, Czechia

Site 702

Moravská Ostrava, Ostrava-město, Czechia

Site 704

Pardubice, Pardubice Region, Czechia

Site 705

Prague, Praha, Hlavní Mesto, Czechia

Site 703

Prague, Praha, Hlavní Mesto, Czechia

Site 303